NVO - FDA approves Wegovy for reduction of cardiovascular risks
2024-03-08 14:28:57 ET
More on Novo Nordisk
- Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
- Novo Nordisk, A Very Healthy Pharma Stalwart
- Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
- Novo Nordisk not planning more supply chain acquisitions: report
- Novo Nordisk sees launching new obesity drugs before Wegovy patent expires